PIP5K1A and pheochromocytoma-paraganglioma: PIP5K1A also exhibited negative correlations with these immune signatures and indicated a poor prognosis in BRCA, CESC, LIHC, PAAD, pheochromocytoma and paraganglioma (PCPG), prostate cancer (PRAD), rectum adenocarcinoma (READ), SKCM, testicular germ cell tumors (TGCT), and thyroid carcinoma (THCA).